Search

everythinglearnresearchcommunity

for

Search:↓

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

The user is pausing finasteride for blood donation and is concerned about its effect on DHT levels. They plan to supplement with saw palmetto and pumpkin seed oil during the pause.

The user has been using finasteride weekly for 3 years and regrew most of their hair. They are asking what to expect if they stop using it for 3 weeks.

Finasteride users cannot donate blood due to potential risks to pregnant women, requiring a one-month cessation before donating. Dutasteride requires a six-month deferral, and topical applications are not restricted.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.

A user experienced erectile issues after 7 months of using Finasteride and sought advice. Responses varied, with some suggesting breaks and others sharing similar side effects or dismissing concerns.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

RU58841 should be stored in the refrigerator to maintain efficacy, but it remains stable for over two years even without refrigeration. A user prefers using Minoxidil and finasteride instead.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation discusses the duration of hair shedding caused by RU58841. The user is stressed and seeking information on how long the shedding phase lasts.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Finasteride may take 8-12 months to show results, with initial shedding common. Users suggest waiting before considering stronger treatments like dutasteride.

The user stopped finasteride for 26 days and is concerned about losing hair regrowth. Another user suggests they will likely return to their pre-stop baseline but advises consulting a doctor.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

The conversation emphasizes the need for patience when using finasteride for hair loss, as it can take up to 2 years to see maximum results, and results vary from person to person. Some users also discuss dosage adjustments and side effects, highlighting individual differences in response to the treatment.

Breezula's phase 3 results are expected soon, but its release is likely delayed until 2027 or 2028. The discussion highlights the need for more hair growth stimulants like AMP-303 and PP-405, as current treatments like Dutasteride effectively stop hair loss but don't regrow hair.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

The conversation discusses concerns about the efficacy of pyrilutamide if left in a mailbox for several hours. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

A user who has been using Pyrilutamide for 5 months with no results, and other users suggesting they switch to RU58841 or stick to their treatment plan for at least one year.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

Finasteride can take years to show results, not months. Dutasteride may work faster but is less commonly prescribed.

The user is considering stopping finasteride after 1.8 years due to concerns about side effects and is exploring alternatives like minoxidil and topical finasteride. They are also considering microneedling and are advised to wait for new treatments like breezula/clascoterone.

Stopping finasteride and minoxidil can cause significant hair shedding, so they should be continued indefinitely. Concerns about finasteride affecting fertility or causing birth defects are mostly unfounded, but some stop for personal reasons.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.